Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain

José Expósito, Isabel Linares, Isabel Castillo, Miguel Martínez, Pilar Vargas, Ismael Herruzo, José Antonio Medina, Amalia Palacios, Eloisa Bayo, Francisco Peracaula, Javier Jaén, José Antonio Sánchez and María José Ortiz

Abstract

Background: Around 27,000 new cases of prostate cancer are diagnosed every year in Spain and 5400 die from this disease. Radiotherapy (RT), alone or combined, has proven to be effective as initial treatment in patients with localized disease. Our objective was to evaluate the use of external beam RT (EBRT) in our region, comparing the indication rate and irradiation rate and examining variability in its application among hospitals.

Methods: We conducted a review of RT guidelines and indication studies for prostate cancer (% expected irradiation). Data were gathered from all twelve public healthcare centers in Andalusia (Spain) on RT-treated prostate cancer patients during 2013 (% actual irradiation) and from nine of the centers on RT discharge reports. Information was classified according to type of hospital, tumor risk category and RT treatment (technique, dosage, volume, toxicity).

Results: The estimated RT rate was 67% (1289/1917), 43% were aged > 70 years, 44.7% had ECOG performance status of 0; 44.7% had high-risk tumors; 57% underwent RT associated with hormone therapy; 70% of patients receiving RT were treated with 3D planning (30% IGRT); and doses were 70–76 Gy in 70% of cases and >76 Gy in 10.7%. Acute gastrointestinal and genitourinary toxicities were < grade 2 in 79 and 89% of patients, respectively. An irradiation rate significantly below the mean for the study was found in four provinces. There was a significant difference among provinces in the distribution of risk groups.

Conclusions: Underutilization of EBRT was estimated to be around 30% in prostate cancer patients, with an elevated variability in irradiation rates among hospitals related to differences in available technology and in the distribution of patients with different risk levels. These data should be a matter of concern to regional health managers, given the negative and measurable impact on the survival of patients.

Keywords: Prostate cancer, Radiotherapy, Variability, Use

Background

Prostate cancer (PrC) is the second most frequent tumor in males in the industrialized world, with an estimated standardized rate (European population) of 62.5 × 10^5 and a mortality of 8.8 × 10^5 (27,852 and 5481 cases, respectively). In Andalusia, a region in southern Spain with 8.4 million inhabitants, PrC represents a total of 3280 new cases/year and 1250 deaths/year [1–3]. An increase in this disease has been detected over the past few decades, probably in part due to a greater use of prostate-specific antigen (PSA) testing, without ruling out the influence of unknown factors [4]. This higher incidence is associated with an increase in the number of patients with localized disease (gland and surrounding anatomical area) at diagnosis, permitting greater disease control by surgery and radiotherapy (RT). The classification in risk degrees for localized disease and prognostic algorithms enable local treatment options to be...
Medical practice variability (MPV) can have a negative impact on health outcomes and cost-effectiveness [8]. MPV has been attributed to differences in the availability (number or geographic proximity) of resources and in the practice of professionals [9]. Previous research in our setting (VARA II), based on a review of clinical records and treatment reports and considering recommended indications, showed that the underutilization of EBRT in lung cancer had a negative impact on patient outcomes [10–12].

The objectives of the present study were to evaluate the use of EBRT as initial treatment for patients with PrC in hospitals in a region of Southern Spain, comparing expected with actual irradiation rates and examining the variability in its application among participating centers and associated factors.

Methods
A longitudinal retrospective study was conducted between January 1 and December 31 2013 in the 12 public hospitals with RT facilities in Andalusia, an autonomous community in southern Spain with 8.4 × 10^6 inhabitants. These centers are distributed among the 8 provinces that form the autonomous community, ensuring coverage of the whole population.

We gathered data on all patients with non-metastatic PrC of any histological type and degree of risk whose initial treatment was EBRT. This information was obtained from the clinical management computer systems associated with the RT equipment (Varis®, Lantis®, Impac®, Mosaïq® networks, etc.). Demographic data were gathered from the Spanish National Institute of Statistics (http://www.ine.es) [13], while information on cancer incidence and distribution among histological types and stages were extrapolated using data from the 2010 National Prostate Cancer Registry [14] and Carlos III Health Institute (Madrid) [15]. The irradiation rate was obtained by calculating the percentage of irradiated cases with respect to the total number of diagnosed cases, examining the variability by hospital/catchment area. Expected irradiation rates were based on the studies by Tyldesley S et al. and Delaney et al. [16, 17], which define the proportion of patients at each risk level for whom RT (external beam or brachytherapy) would be indicated. Data were gathered from the clinical records on the general state of patients as measured with the ECOG Performance Status (PS) score.

Acute toxicity data were measured following the EORTC/RTOG criteria.

EBRT application variability was studied by analyzing the cases treated in nine of the participating centers, gathering data on the characteristics of the hospital (treatment units/professionals), patients, therapies, and tumors (histology, stage) and on the RT modalities and regimens (doses and combination with hormone therapy [HT]) (Table 1). We excluded patients treated after surgery or after biochemical recurrence and those receiving palliative treatment for bone metastases. Information on each patient was extracted from treatment discharge reports by trained personnel under the supervision of the research team.

Ethical approval
The study has been approved by the provincial Biomedical Research Ethics Committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All patients gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study have been omitted.

Statistical analysis
A descriptive analysis was performed, calculating central tendency and dispersion statistics (mean, median, interquartile range, standard deviation, 95% confidence interval). The chi-square (χ²) test was used to compare qualitative variables and exact Fisher’s test for binary variables. Relationships among quantitative variables were studied by using Pearson’s correlation coefficient (or the non-parametric Kendall’s Tau-b and Spearman tests) and linear regression analysis. A two-sided \( p < 0.05 \) was considered significant. SPSS version 12.0 was used for statistical analyses.

| Table 1 Study variables |
|-------------------------|
| Tumor | Histology, classification (low, intermediate, and high risk), diagnosis date, and Performance Score |
| RT treatment | Dates of start and end of RT, volume, total dose, dose fraction, technique, energy, acute toxicity, interruptions and cause, associated hormone therapy, duration and drugs. |
Results

Irradiation rate

Among patients with PrC, 88 % are expected to have localized disease at their diagnosis, estimating an optimal irradiation rate of 58 % with EBRT and 9 % with brachytherapy [18]. Accordingly, 1917 of the present series of PrC patients would be expected to undergo RT, 41 % of low-risk (n = 1183), 25 % of intermediate-risk (721), and 31 % of high-risk (n = 894) patients. In fact, only 1160 of the patients received EBRT and 129 brachytherapy, i.e., 67 % of the expected total.

EBRT type and variability

As shown in Table 2, the type of EBRT treatment was recorded in 609 (52.50 %) of the 1160 irradiated patients; 43 % were aged > 70 years; 47.6 % were in a good general state (PS = 0); 44.7 % had high-risk, 32 % intermediate-risk, and 23 % low-risk disease. 57 % received RT combined with HT; 67 % of patients received a combined RT-HT therapy (we are excluding patients with BQT (14.4 %). On the other hand, the percentage of patients receiving a combined RT-HT stratified by risk group was as follows: 23 % for low-risk patients, 71.5 % for intermediate-risk patients, and 89.5 % for high-risk patients. Excluding those patients treated with BQT as monotherapy, 72.5 % of patients were irradiated using 3D planning techniques; 70.7 % received 76 Gy (1.8–2 Gy/fr) and 10.8 % were prescribed higher doses than 76 Gy (1.8–2Gy/fr). 18.5 % received less than 76 Gy but using a hypo-fractionation scheme with doses-per-fraction > 2 Gy. Volumes were centered on prostate gland in 64 % and seminal vesicles in 23 %. Only 12.9 % received RT to the lymph nodes; this might be explained by the fact that 46.3 % of patients were both high-risk and aged 70 years or more, indicating clinicians reluctance and true concern to prescribed lymph nodes RT in patients identified as frail, elderly patients, in order to avoid a live-threatening toxicity. Acute intestinal and genitourinary toxicities were < grade 2 in 79 and 89 % of patients, respectively.

Irradiation dosages and volumes were significantly correlated with risk levels (Table 3). A high risk was associated with doses >76 Gy (p < 0.003) and with the inclusion of vesicles and lymph nodes in the target volume (p < 0.001). However, neither intestinal nor urinary toxicity was correlated with the total dose, treated volume, or degree of risk.

The participating hospital centers showed significant differences in the irradiation rate. As shown in Table 4, a significantly lower number of patients underwent RT than expected in hospitals 3, 6, 7, and 8, whereas a significantly higher number than expected was treated in hospital 4 (Table 4). There was also a difference in the distribution of risk groups (Fig. 1), with a significantly higher proportion of high-risk patients in hospitals 5 and 6 than in the others. Concerning the analysis of

Table 2 Main variables characteristics

| Age (ranges) | 40–60 | 77 (12.6 %) |
|-------------|-------|-------------|
| 61–70       | 262 (43 %) |
| >70         | 265 (43.5 %) |
| Unknown     | 5 (0.8 %) |
| Performance score | 0 | 290 (47.6 %) |
| 1           | 72 (11.8 %) |
| 2           | 1 (0.2 %) |
| 3           | 1 (0.2 %) |
| Unknown     | 245 (40.2 %) |
| Risk (D’Amico) Low | 140 (23 %) |
| Intermediate | 195 (32 %) |
| High        | 272 (44.7 %) |
| Unknown     | 2 (0.3 %) |
| Treatment RT | 85 (14 %) |
| RT + HT     | 348 (57.1 %) |
| Cx + RT     | 87 (14.3 %) |
| BQ          | 88 (14.4 %) |
| Unknown     | 1 (0.2 %) |
| RT technique 3D | 369 (60.6 %) |
| IGRT        | 140 (23.0 %) |
| BQ          | 88 (14.4 %) |
| Unknown     | 12 (2.0 %) |
| RT dose (Gy) <76 | 96 (15.8 %) |
| 76          | 367 (60.3 %) |
| >76         | 56 (9.2 %) |
| Unknown     | 2 (0.3 %) |
| BQ          | 88 (14.4 %) |
| Volumea Prostate | 331 (63.5 %) |
| + Vesicles  | 119 (22.8 %) |
| + Lymph nodes | 67 (12.9 %) |
| Unknown     | 4 (0.8 %) |
| Toxicityb GI 0 | 218 (41.8 %) |
| 1           | 175 (33.6 %) |
| 2           | 86 (16.5 %) |
| 3           | 2 (0.4 %) |
| Unknown     | 40 (7.7 %) |
| GIU 0       | 432 (82.9 %) |
| 1           | 38 (7.3 %) |
| 2           | 14 (2.7 %) |
| 3           | 1 (0.2 %) |
| Unknown     | 36 (6.9 %) |

RT radiotherapy, HT hormone therapy, Cx surgery, IGRT image-guided radiation therapy, GI gastrointestinal, GU genitourinary

aTreatment volume excluding Brachytherapy

bToxicity excluding Brachytherapy
other variables, such as total dose, dose per fraction and technique, some differences between hospitals were found. Regarding total dose most centers prescribed 76 Gy in 70–90% of cases. Only in hospital 6 and 7 was a total dose < 76 Gy prescribed, but using an hypofractionated scheme with doses per fraction >2Gy; it should be pointed out that these hospitals had at their disposal IGRT systems. Hospital 3 was the one who presented the highest percentage of patients treated with total doses > 76 Gy. Regarding the techniques used in each center, hospital 1, 2 and 3 lacked any IGRT system. Hospital 1, 3 and 5 did not have BQT and the percentage of patients being treated with this technique (referring patients to other centers) was lower than the rest of centers.

Discussion
Knowledge of irradiation rates defines the contribution of radiation oncologist to the management of cancer patients and is important for the allocation of RT resources [19, 20]. Various methods have been proposed to estimate the irradiation rate as accurately as possible, following benchmarking [21], expert, or evidence-based criteria [22]. The most updated approach [18] was used in this study of hospitals in a southern Spanish region, which found that EBRT was not administered to almost three out of every ten patients who could have been expected to receive it.

There are various possible explanations for this apparent underutilization of RT. Urologists, who initiate the PrC diagnostic process, may be more inclined to support surgery rather than EBRT, especially in low- and intermediate-risk patients, who represented a large proportion of the present series. Thus it would be important to develop multidisciplinary teams, in order to better assign patients who might benefit from a RT treatment. We highlight the finding that image-guided RT, considered the most effective technique [23], was only possible in 30% of the patients, concentrated in the three centers possessing this facility at the time of the study. Despite efforts to improve the situation over the past few years, the availability of this technology remains suboptimal in Andalusia [3, 24]. Technological limitations may also account for the low total dosages and little utilization of doses > 2 Gy per fraction (hypofractionation), a widespread approach in PrC treatment, although it may also reflect certain reservations among professionals about the application and safety of less standard techniques [11]. The low dosages may in part explain the low toxicity levels, but further research is required to establish their effect on final patient outcomes and compare these with other reports [25]. Another technological limitation in Andalusia was that only 4 centers were able to offer a brachytherapy treatment to patients having a low-risk which, as it is already well established in the literature, is an alternative to other

| Table 3 | Relationship of risk with variables |
|---------|-----------------------------------|
| Variables                                | Pearson’s Chi² test | P         | Comment               |
| Risk– total dose                         | 15.738              | 0.003     | Higher risk, higher dose |
| Risk – dose fraction                     | 30.746              | 0.000     | Higher risk, higher dose |
| Risk – volume                            | 121.225             | 0.000     | Higher risk, higher dose |
| Risk – urinary toxicity                  | 8.602               | 0.197     | No relationship        |
| Risk – gastrointestinal toxicity         | 3.608               | 0.730     | No relationship        |

| Table 4 | Distribution of expected and observed cases by center |
|---------|------------------------------------------------------|
|         | Hospital by province | Population | Expected Frequency | Expected Rate (cases/10000 inhabitants) | 95% CI low | high | Observed Frequency | Observed rate (cases/10000 inhabitants) | 95% CI low | high |
|---------|----------------------|------------|--------------------|-----------------------------------------|-----------|------|--------------------|-----------------------------------------|-----------|------|
| 3       | 518 687              | 103        | 1.99               | 1.60                                    | 2.37      | 83   | 1.60               | 1.26                                    | 1.94      |
| 11      | 698 601              | 130        | 1.86               | 1.54                                    | 2.18      | 108  | 1.55               | 1.25                                    | 1.84      |
| 86      | 700 570              | 139        | 1.98               | 1.65                                    | 2.31      | 90   | 1.28               | 1.02                                    | 1.55      |
| 64      | 798 580              | 158        | 1.98               | 1.67                                    | 2.29      | 258  | 3.23               | 2.64                                    | 3.63      |
| 27      | 918 382              | 182        | 1.98               | 1.69                                    | 2.27      | 185  | 2.01               | 1.72                                    | 2.31      |
| 4,56    | 1 238 291            | 246        | 1.99               | 1.74                                    | 2.24      | 44   | 0.36               | 0.25                                    | 0.46      |
| 1,10,96 | 1 619 497            | 321        | 1.98               | 1.77                                    | 2.20      | 211  | 1.30               | 1.13                                    | 1.48      |
| 9       | 1 940 027            | 385        | 1.98               | 1.79                                    | 2.18      | 300  | 1.55               | 1.37                                    | 1.72      |

*Significant differences between observed and expected values
Another important issue in terms of variability would be the importance of active vigilance in a subset of patients with low-risk; even if this active surveillance is a recommended option [27] for this group of patients, especially the older one among them, in Andalusia is not still an option currently offered to our patients. At least, authors of this article have no record of it.

Besides differences in equipment, the elevated variability among hospitals would also be related to variations in the distribution of patients with different risk levels. Thus, hospitals 5 and 6 had a much larger percentage of high-risk patients, which would imply a more frequent use of surgery as local treatment.

Besides all of these causes mentioned above, we have to conclude that an important part of the variability found within Andalusia is due to an intrinsic variability between physicians.

Study limitations include the lack of data on treatment regimens from three hospitals and the non-participation of private centers, although these only represent around 15–10% of PrC patients in our region. However, relevant information was obtained on the inadequacy and variability of RT utilization, making the case for a greater prioritization of scarce resources to remedy this situation [28].

Given the impediments to conducting clinical trials on RT, further research is warranted to compare its utilization and outcomes in different cancer types among centers with varied technological resources [29, 30].

Conclusions
In representative public hospitals from our region, radiotherapy was not delivered to around 30% of prostate cancer patients who could benefit from this treatment. An elevated variability among centers in the irradiation rate was related to differences in risk distribution and the availability of high-performance radiation therapy. These data should be a matter of concern to regional health authorities, given the measurable negative impact on the survival of patients.

Abbreviations
EBRT: external beam radiotherapy; HT: hormone therapy; MPV: medical practice variability; PrC: prostate cancer; PS: performance status; PSA: prostate-specific antigen; RT: radiotherapy.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Author details
1Radiotherapy and Oncology Department, Granada General Hospital, Avda. fuerzas Armadas, s/n, 18014 Granada, Spain. 2Radiotherapy and Oncology Department, Granada General Hospital, Calle Dr. Oloriz, 16, 18012 Granada, Spain. 3Radiotherapy and Oncology Department, Jaén General Hospital, Avda. del Ejército Español, 10, 23007 Jaén, Spain. 4Radiotherapy and Oncology Department, Carlos Haya University Hospital, Avenida Carlos Haya, s/n, 29010 Málaga, Spain. 5Radiotherapy and Oncology Department, Virgen de la Victoria University Hospital, Campus de Teatinos, s/n, 29010 Málaga, Spain. 6Radiotherapy and Oncology Department, Reina Sofia University Hospital, Avda. Menéndez Pidal, s/n, 14004 Córdoba, Spain. 7Radiotherapy and Oncology Department, Juan Ramón Jiménez Hospital, Avda. de la Orden, 21005 Huelva, Spain. 8Radiotherapy and Oncology Department, Punta de Europa Algeciras Hospital, Carr Getares, S/N, 11207 Algeciras, Cádiz, Spain. 9Radiotherapy and Oncology Department, Puerta del Mar University Hospital, Av. Aña de Vuya, 21, 11009 Cádiz, Spain. 10Radiotherapy and Oncology Department, Virgen Macarena University Hospital, Avda. Dr Fedriani, 3, 41071 Sevilla, Spain. 11Radiotherapy and Oncology Department, Virgen del Rocío University Hospital, Avda. Manuel Siurot, s/n, 41013 Sevilla, Spain.

Received: 19 June 2015 Accepted: 15 December 2015

Published online: 30 December 2015
References

1. Globocan 2012. http://globocan.iarc.fr/Default.aspx.
2. Eurocare 2008. http://www.eurocare.it/AboutUs/tabid/54/Default.aspx.
3. Expósito J. (coord.) Comprehensive Andalusia Cancer Plan 2007–2012. Consejería de Salud. 2007.
4. Chamie K, Williams SB, Hu JC. Population-based assessment of determining treatments for prostate cancer. JAMA Oncol. 2015; doi:10.1001/jamaoncol.2014.192.
5. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. Am:heurn (The Netherlands): European Association of Urology (EAU). 2013, p. 154.
6. Fowler FJ, Barry MJ, Lu-Yao G, et al. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance epidemiology and end results areas. J Clin Oncol. 1996;4:2258–65.
7. Slotman BJ, Vos PH. Planning of radiotherapy capacity and productivity. Radiother Oncol. 2013;106:266–70.
8. Kilidong M, van Dijk BA, Otter R, et al. Regional variation in breast cancer treatment in the Netherlands and the role of external peer review: a cohort study comprising 65,516 women. BMC Cancer. 2014;14:536.
9. Grua C, Defourny N, Malicki J, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):155–64.
10. Tovar I, Expósito J, Jaén J, et al. Underuse of radiotherapy in lung cancer has negative consequences for patients. J Thorac Oncol. 2013;8(11):62–7.
11. Expósito J, Jaén J, Alonso E, et al. Use of palliative radiotherapy in brain and bone metastases (VARA II study). Radiat Oncol. 2012;7:131–6.
12. Tovar I, Expósito J, Jaén J, et al. Pattern of use of radiotherapy for lung cancer: a descriptive study. BMC Cancer. 2014;14:697–702.
13. National Institute of Statistic, Spanish Health Ministry. http://www.ine.es.
14. Córza JM. Registro Nacional de Cáncer de próstata 2010 en España. Acta Urológica Española. 2013:37. doi:10.1016/j.acuro.2012.06.006.
15. Situación del cáncer en España. Instituto Carlos III (Madrid) 2009. http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/epicancer/junio2009-revisado2.pdf.
16. Tyldeley J, Delaney G, Foroudi F, et al. Estimating the need for radiotherapy for prostate patients, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys. 2011;79(5):1507–15.
17. Delaney GP, et al. Evidence-based estimates of demand for radiotherapy. Clin Oncol. 2014;1–7. doi:10.1016/j.clon.2014.10.005.
18. Barton M, Jacob S, Shafiq J, et al. Review of optimal radiotherapy utilization rates. Ingham Institute. March 2013. http://inghaminstitute.org.au/sites/default/files/RTU_Review_Final_v3_02042013.pdf.
19. Kerba M, Miao Q, Zhang- Salomons J, MacLillock W. Defining the need for prostate cancer radiotherapy in general population: a criterion based benchmarking approach. Clin Oncol. 2010;22:801–9.
20. Bentzen SM, Heeren G, Cottier B, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75:355–6.
21. Kerba M, Miao Q, Zhang-Salomons J, et al. Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol (R Coll Radiol). 2007;19(7):481–9.
22. Jaén J, Alonso E, Expósito J, de las Peñas MD, Cabrera P. Evidence-based estimation and radiotherapy utilization rate, in Andalusia. Clin Transl Oncol. 2007;9:789–95.
23. Zelensky MJ, Kollmeier M, Brett Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125–9.
24. On behalf of the HERO consortium, Dunscombe P, Grau C, Defourny N, Malicki J, et al. Guidelines for equipment and staffing of radiotherapy facilities in the Europe countries: final results of the ESTRO-HERO survey. Radiother Oncol. 2014;112:165–77.
25. Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li H. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol. 2014;9:275. doi:10.1186/s13014-014-0275-6.
26. Nag S, Beber D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–99.
27. Bill-Axelson A, Garmo H, Holmberg L, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013;64(6):920–8.
28. López-Torrejón J, Zapatero A, Herruzo I, Calvo FA, et al. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer. Clin Transl Oncol. 2014;16:447–54.
29. van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol. 2013;14:169–77.
30. Sullivan R et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933–80.